ALLYL GLYCOSIDES;
BUILDING BLOCKES;
EFFICIENT SYNTHESIS;
IMMUNOADJUVANTS;
CHEMISTRY;
ORGANIC COMPOUNDS;
2,3,4 TRI O ACETYL BETA DEXTRO XYLOPYRANOSYL(1-3) 2,4 DI O ACETYL BETA DEXTRO XYLOPYRANOSYL(1-4) 2,3 DI O ACETYL ALPHA LEVO RHAMNOPYRANOSYL( 1-2) 3,4 DI O ACETYL ALPHA DEXTRO FUCOPYRANOSYL TRICHLOROACETIMIDATE;
2,3,4 TRI O ACETYL BETA DEXTRO XYLOPYRANOSYL(1-4) 2,3 DI O ACETYL ALPHA LEVO RHAMNOPYRANOSYL(1-2) 3,4 DI O ACETYL ALPHA DEXTRO FUCOPYRANOSYL TRICHLOROACETIMIDATE;
2,3,5 TRI O ACETYL BETA DEXTRO APIOFURANOSYL (1-3) 2,4 DI O ACETYL BETA DEXTRO XYLOPYRANOSYL(1-4) 2,3 O DIACETYL ALPHA LEVO RHAMNOPYRANOSYL(1-2) 3,4 DI O ACETYL ALPHA DEXTRO FUCOPYRANOSYL TRICHLOROACETIMIDATE;
ALLYL 2,3 O ISOPROPYLIDENE ALPHA LEVO RHAMNOPYRANOSYL(1-2) 3,4 O ISOPROPYLIDENE ALPHA DEXTRO FUCOPYRANOSIDE;
ALLYL 2,3,4 TRI O PIVALOYL ALPHA DEXTRO XYLOPYRANOSIDE;
ALLYL 2,3,4 TRI O PIVALOYL BETA DEXTRO XYLOPYRANOSYL(1-3) 2,4 DI O PIVALOYL BETA DEXTRO XYLOPYRANOSYL(1-4) 2,3 O ISOPROPYLIDENE ALPHA LEVO RHAMNOPYRANOSYL( 1-2) 3,4 O ISOPROPYLIDENE ALPHA DEXTRO FUCOPYRANOSIDE;
ALLYL 2,3,4 TRI O PIVALOYL BETA DEXTRO XYLOPYRANOSYL(1-3) 2,4 DI OPIVALOYL ALPHA DEXTRP XYLOPYRANOSIDE;
ALLYL 2,3,4 TRI O PIVALOYL BETA DEXTRO XYLOPYRANOSYL(1-4) 2,3 O ISOPROPYLIDENE ALPHA LEVO RHAMNOPYRANOSYL(1-2) 3,4 O ISOPROPYLIDENE ALPHA DEXTRO FUCOPYRANOSIDE;
ALLYL 2,3,5 TRI O ACETYL BETA DEXTRO APIOFURANOSYL(1-3) 2,4 DI O PIVALOYL BETA DEXTRO XYLOPYRANOSYL(1-4) 2,3 O ISOPROPYLIDENE ALPHA LEVO RHAMNOPYRANOSYL( 1-2) 3,4 O ISOPROPYLIDENE ALPHA DEXTRO FUCOPYRANOSIDE;
ALLYL 2,3,5 TRI O ACETYL BETA DEXTRO APIOFURANOSYL(1-3) 2,4 DI OPIVALOYL BETA DEXTRO XYLOPYRANOSIDE;
ALLYL 2,4 DI O PIVALOYL ALPHA DEXTRO XYLOPYRANOSIDE;
ALLYL 3,4 ISOPROPYLIDENE ALPHA DEXTRO FUCOPYRANOSIDE;
ALLYL 4 O ACETYL 2,3 O ISOPROPYLIDENE ALPHA LEVO RHAMNOPYRANOSIDE;
GLYCOSIDE;
IMMUNOLOGICAL ADJUVANT;
QS 21;
UNCLASSIFIED DRUG;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ARTICLE;
CONTROLLED STUDY;
DRUG STRUCTURE;
DRUG SYNTHESIS;
FEMALE;
GLYCOSYLATION;
MOUSE;
NONHUMAN;
In; Hackett, C. J. Harn, D. A. J. Humana Press Inc. Totowa, NJ
Kensil, C. R.; Liu, G.; Anderson, C.; Storey, J. In Vaccine Adjuvants: Immunological and Clinical Principles; Hackett, C. J.; Harn, D. A. J., Eds.; Humana Press Inc.: Totowa, NJ, 2005; p 221.
Marciani, D.; Press, J. B.; Reynolds, R. C.; Pathak, A. K.; Pathak, V.; Gundy, L. E.; Farmer, J. T.; Koratich, M. S.; May, R. D. Vaccine 2000, 18, 3141
Marciani, D. J.; Ptak, R. G.; Voss, T. G.; Reynolds, R. C.; Pathak, A. K.; Chamblin, T. L.; Scholl, D. R.; May, R. D. Int. Immunopharmacol. 2002, 2, 1703
Chea, E. K.; Fernandez-Tejada, A.; Damani, P.; Adams, M. M.; Gardner, J. R.; Livingston, P. O.; Ragupathi, G.; Gin, D. Y. J. Am. Chem. Soc. 2012, 134, 13448